Fig. 4From: Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectivelyEffects of ibrutinib on immune cells and tumor microenvironment. BTLA, B- and T-lymphocyte attenuator; IL-10, interleukin 10; NAMPT, Nicotinamide Phosphoribosyltransferase; PD-L1, programmed cell death protein ligand 1; TCR, T-cell receptorBack to article page